News | December 25, 2023
Lyndra Therapeutics raises US$101 million in Series E funding
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries
Softovac Liquifibre expands the Softovac product portfolio and provides a choice for consumers who prefer time-tested Ayurvedic ingredients
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
The Regional Reference Laboratory in Chennai is equipped with cutting-edge diagnostic technologies
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Subscribe To Our Newsletter & Stay Updated
